ISS Recommends That Engelhard's Shareholders Vote 'FOR' BASF's Nominees
Geschrieben am 24-05-2006 |
Ludwigshafen, Germany (ots/PRNewswire) -
BASF Aktiengesellschaft (Frankfurt: BAS, NYSE: BF [ADR], LSE: BFA, SWX: AN) today announced that Institutional Shareholder Services (ISS) has recommended that Engelhard's shareholders vote for BASF's five nominees for election to Engelhard's Board of Directors at the June 2 Annual Shareholders' Meeting.
ISS is a highly respected, independent proxy advisory firm, and its voting analyses and recommendations are relied upon by hundreds of institutional investors, mutual funds, and fiduciaries throughout the world.
BASF is pleased that ISS has recognized the value and certainty of BASF's all-cash offer and recommended that Engelhard's shareholders vote "FOR" BASF's nominees.
BASF is the world's leading chemical company: The Chemical Company. Its portfolio ranges from chemicals, plastics, performance products, agricultural products and fine chemicals to crude oil and natural gas. As a reliable partner to virtually all industries, BASF's intelligent system solutions and high-value products help its customers to be more successful. BASF develops new technologies and uses them to open up additional market opportunities. It combines economic success with environmental protection and social responsibility, thus contributing to a better future. In 2005, BASF had approximately 81,000 employees and posted sales of more than EUR42.7 billion. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA), New York (BF) and Zurich (AN). Further information on BASF is available on the Internet at www.basf.com.
BASF is currently soliciting proxies for use at Engelhard's 2006 annual meeting of stockholders, or at any adjournment or postponement thereof, to vote in favor of BASF's nominees identified in the definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the "SEC") on May 12, 2006, and to vote on any other matters that shall be voted upon at Engelhard's 2006 annual meeting of stockholders. All Engelhard stockholders are strongly encouraged to read the definitive proxy statement, because it contains important information. Engelhard stockholders may obtain copies of the definitive proxy statement and related materials for free at the SEC's website at www.sec.gov.
The identity of people who may be considered "participants in a solicitation" of proxies from Engelhard stockholders for use at Engelhard's 2006 annual meeting of stockholders under SEC rules and a description of their direct and indirect interests in the solicitation, by security holdings or otherwise, are contained in the definitive proxy statement on Schedule 14A that BASF filed with the SEC on May 12, 2006.
BASF may also solicit written consents of Engelhard stockholders to (a) amend the bylaws of Engelhard to increase the number of directors on Engelhard's Board of Directors to twelve and provide that any newly created vacancies on Engelhard's Board of Directors shall be filled by Engelhard's stockholders, and (b) to appoint individuals selected by BASF to fill the vacancies created thereby (the "Proposals"). Full details of the Proposals are contained in the preliminary consent solicitation statement on Schedule 14A that BASF filed with the SEC on May 15, 2006. All Engelhard stockholders are strongly encouraged to read the preliminary consent statement and the definitive consent statement when they are available because they will contain important information. Engelhard stockholders may obtain copies of the preliminary consent statement and related materials for free at the SEC's website at www.sec.gov. The identity of people who, under SEC rules, may be considered "participants in a solicitation" of consents for the Proposals and a description of their direct and indirect interests in the solicitation, by security holdings or otherwise, are contained in the preliminary consent statement on Schedule 14A filed with the SEC on May 15, 2006.
This press release is provided for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of Engelhard Corporation. Any offers to purchase or solicitation of offers to sell will be made only pursuant to the tender offer statement (including the offer to purchase, the letter of transmittal and other offer documents) which was initially filed with the SEC on January 9, 2006. Engelhard stockholders are advised to read these documents and any other documents relating to the tender offer that are filed with the SEC carefully and in their entirety because they contain important information. Engelhard stockholders may obtain copies of these documents for free at the SEC's website at www.sec.gov or by calling Innisfree M&A Incorporated, the Information Agent for the offer, at +1 877 750 5837 (Toll Free from the U.S. and Canada) or 00800 7710 9971 (Toll Free from Europe).
This press release contains forward-looking statements. All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections of BASF management and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict and are based upon assumptions as to future events that may not prove to be accurate.
Many factors could cause the actual results, performance or achievements of BASF to be materially different from those that may be expressed or implied by such statements. Such factors include those discussed in BASF's most recent Form 20-F filed with the SEC.
Michael Grabicki Phone: +49-621-60-99938 Fax: +49-621-60-92693 michael.grabicki@basf.com US media contact: Rand Pearsall Phone: +1-973-245-6820 Fax: +1-973-245-6714 rand.pearsall@basf.com Analysts/Investors contact: Christoph Beumelburg Phone: +1-973-245-6013 Cell: +1-973-519-2981 Fax: +1-973-245-6714 christoph.beumelburg@basf.com
Web site: http://www.basf.com
ots Originaltext: BASF Aktiengesellschaft Im Internet recherchierbar: http://www.presseportal.de
Contact: Michael Grabicki, +49-621-60-99938, fax +49-621-60-92693, michael.grabicki@basf.com, US - Rand Pearsall, +1-973-245-6820, fax, +1-973-245-6714, rand.pearsall@basf.com, Investors - Christoph Beumelburg, Phone, +1-973-245-6013, Cell, +1-973-519-2981, Fax, +1-973-245-6714, christoph.beumelburg@basf.com
Kontaktinformationen:
Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.
Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.
Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.
http://www.bankkaufmann.com/topics.html
Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.
@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf
E-Mail: media(at)at-symbol.de
14172
weitere Artikel:
- euro adhoc: Advanced Medien AG / Geschäftszahlen/Bilanz / Advanced Medien AG gibt vorläufige Zahlen für das Geschäftsjahr 2005 bekannt. -------------------------------------------------------------------------------- Ad hoc-Mitteilung übermittelt durch euro adhoc. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 24.05.2006 München, 24. Mai 2006 - Die Advanced Medien AG, München (ISIN DE0001262186, WKN 126218), schloss die Neuorientierung ihres Geschäftes im vergangenen Geschäftsjahr erfolgreich ab. Der Konzern erzielte in 2005 einen Umsatz in Höhe von EUR 25,9 Mio. nach EUR 14,8 Mio. im Vergleichszeitraum mehr...
- Christal Films sichert sich Rechte zum Verleih des nächsten Woody-Allen-Films für Kanada Montreal, Kanada (ots/PRNewswire) - Es gibt auch in diesem Jahr auf dem Filmmarkt von Cannes wieder einige grosse Filmprojekte, und Christal Films Distribution ist stolz darauf, sich die Rechte für einen dieser Filme gesichert zu haben: Die Dreharbeiten zu Woody Allens nächstem Film werden im Juni in London beginnen. Christian Larouche und Sylvain Gagné (President bzw. Vice-President von Christal Films) liessen sich beide vom Charme der herrlichen Mischung aus Romanze und Hitchcock-Thriller gefangen nehmen und freuen sich darauf, die Originalität mehr...
- Aktien mit zufallsbedingten Kursentwicklungen bei ruhigem Handel - Emerging-Market-Fonds eher nachgebend Berlin (ots) - Eigentlich konnten die Anleger mit den heutigen Vorgaben ganz zufrieden sein, Dow und Nasdaq boten Plus-Vorgaben. Es gab keine besonderen negativen Unternehmens-Nachrichten.Die Tokioter Börse schloss heute allerdings schwach, wobei rückläufige Rohstoffpreise belasteten. Die Berliner Marktteilnehmer starteten heute ganz zuversichtlich, wobei DAX und MDAX freundlicher tendierten. Viele Anleger hierzulande atmeten jetzt möglicherweise erst einmal auf. Die letzten Tage an den deutschen Börsen hatten doch für Unsicherheit gesorgt mehr...
- Isotechnika Signs Agreement Granting Lux Biosciences Worldwide Ophthalmic Rights to ISA247 Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika's lead drug, ISA247 for the treatment and prophylaxis of all ophthalmic diseases. ISA247 is a novel calcineurin inhibitor currently being investigated in a Phase III trial for the treatment of moderate to severe psoriasis and a Phase IIb trial for the prevention of organ rejection following mehr...
- Osteologix, Inc. schliesst am Mittwoch, den 24. Mai 2006 Reverse Merger ab San Francisco (ots/PRNewswire) - - Sichert USD 10 Mio an Finanzierung durch Privatplatzierung Osteologix, Inc. ein Biopharmazeitischen Unternehmen mit Hauptsitz in San Francisco, Kalifornien, und Niederlassungen in Kopenhagen, Dänemark, gab heute den Abschluss eines Reverse Merger und Aktientausch-Transaktion mit dem in New York, NY, ansässigen, öffentlich gehandelten Unternehmen Castle & Morgan Holdings, Inc. (OTC) bekannt. Neben dem Zusammenschluss gab Osteologix ausserdem bekannt, dass das Unternehmen eine Finanzierung durch Privatplatzierung mehr...
|
|
|
Mehr zu dem Thema Finanzen
Der meistgelesene Artikel zu dem Thema:
Century Casinos wurde in Russell 2000 Index aufgenommen
durchschnittliche Punktzahl: 0 Stimmen: 0
|